Sorin Group S.p.A. (SRN) Announces First U.S. Implant of PARADYM RF SonR® CRT-D* for RESPOND CRT IDE Clinical Trial
6/20/2013 9:21:15 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MILAN--(BUSINESS WIRE)--Sorin Group (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and leader in the treatment of cardiovascular diseases, announces the first U.S. implant of its PARADYM SonR CRT System for the RESPOND CRT IDE Clinical Trial. Dr. B. A. Smith, Electrophysiologist, Piedmont Heart Institute, Atlanta, GA, performed the procedure on May 30.
Help employers find you! Check out all the jobs and post your resume.
comments powered by